| abstract |
The present invention relates to a compound of formula I n n n n n n n n n n whereinn nAr 1 , Ar 2 , R 1 , R 2 , R 3 , n, o, and p are as described hereinn nor to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |